CSIMarket
 
Vaxxinity Inc   (NASDAQ: VAXX)
Other Ticker:  
 
 
Price: $0.0001 $0.00 0.000%
Day's High: $0.01 Week Perf: 0.00
Day's Low: $ 0.01 30 Day Perf: -95 %
Volume (M): 3 52 Wk High: $ 1.10
Volume (M$): $ 0 52 Wk Avg: $0.32
Open: $0.01 52 Wk Low: $0.00



 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 127
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -57
 Cash Flow (TTM) (Millions $) -30
 Capital Exp. (TTM) (Millions $) 1

Vaxxinity Inc
Vaxxinity Inc is a biotechnology company that specializes in the development and production of vaccines for infectious diseases. The company was established in 2016, with its headquarters located in Boston, Massachusetts, USA. The company's main mission is to improve global health by preventing the spread of infectious diseases through the development and distribution of safe and effective vaccines.

Vaxxinity Inc's vaccine development platform combines in-house research with collaborations with academic institutions, government agencies, and industry partners. The company's approach is to develop vaccines that stimulate the body's immune system to fight infectious diseases. They believe that this approach is safer and more effective than traditional methods, such as attenuated or inactivated vaccines.

The company has an impressive portfolio of vaccines that are either in development or already approved for use. Some of the vaccines in their pipeline include vaccines for COVID-19, Zika virus, influenza, and rabies. Vaxxinity Inc's COVID-19 vaccine, VXN-19, is a protein-based vaccine that targets the spike protein of the SARS-CoV-2 virus. The vaccine is currently in phase II clinical trials and has shown promising results in preclinical studies.

Aside from vaccine development, Vaxxinity Inc is also involved in vaccine manufacturing and distribution. The company has partnerships with several contract manufacturing organizations (CMOs) to produce its vaccines in large quantities. They also have collaborations with government agencies, non-profit organizations, and other commercial partners to distribute their vaccines to those who need them the most, particularly in low- and middle-income countries.

Vaxxinity Inc is a relatively new company, but it has already gained recognition in the biotechnology industry for its innovative approach to vaccine development. The company has a team of experienced scientists, researchers, and business executives who are committed to achieving their mission of improving global health through the development of safe and effective vaccines.


   Company Address: 505 Odyssey Way Merritt Island 32953 FL
   Company Phone Number: 244-5739   Stock Exchange / Ticker: NASDAQ VAXX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BMY   -3.7%    
EBS   -8.7%    
FGEN   -8.7%    
OPK   -1.59%    
PFE   -1.75%    
REGN        2.15% 
• View Complete Report
   



Stock Market Announcement

Vaxxinity's Strategic Vision Paves the Way for Shareholder Success

Published Fri, Apr 19 2024 10:53 PM UTC


In a recent press release, Vaxxinity, Inc. showcased its commitment to innovation and advancement in the pharmaceutical industry. The company, pioneering the development of a groundbreaking class of medicines, issued a shareholders letter signed by the Co-founder and Executive Chairman, Lou Reese, and Chief Executive Officer, Mei Mei Hu.
Vaxxinity, Inc., a U.S. base...

Vaxxinity Inc

VAXX Reports Earnings for Fiscal Period Ending December 31, 2023, Amid Industry Analysis

The Major Pharmaceutical Preparations sector researchers have recently begun analyzing the fourth quarter performance of 2023. One company in particular, Vaxxinity Inc, has caught their attention due to its operating shortfall of $-25.05 million for the period. It is worth noting that Vaxxinity Inc has not yet reported its top-line figures for this reporting season.
To provide some context, let's compare this performance to the previous year. In the fourth quarter of 2022, Vaxxinity Inc reported an operating shortfall of $-20.823 million. This suggests a slight increase in the operating shortfall for the current period. The company's CFO is working on implementing different corporate policies to ensure a steady revenue source.

Clinical Study

Vaxxinity's Breakthrough Immunotherapy, UB-312, Shows Promise in Reducing Pathological Alpha-Synuclein in Parkinson's Patients

Published Thu, Mar 7 2024 3:32 PM UTC

Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson's Disease at AD/PD 2024Parkinson's disease is a debilitating neurodegenerative disorder that affects millions of people worldwide. Characterized by the gradual loss of dopamine-producing cells in the brain, Parkinson's leads to motor symptoms such as tremors, stiffness, and difficul...

Product Service News

Vaxxinity's Promising Cholesterol Vaccine Lowers LDL-C: Promising Preclinical Data Paves the Way to Uphold Cardiovascular Disease Management

Published Thu, Feb 15 2024 1:01 PM UTC

Vaxxinity's Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Promising Preclinical Data PublishedPreclinical data published in the Journal of Lipid Research has revealed that Vaxxinity Inc's cholesterol vaccine candidate, VXX-401, demonstrates immense potential in reducing LDL-C levels. These findings are instrumental in the ongoing battle against cardiovascular dise...

Vaxxinity Inc

Breakthrough COVID-19 Vaccine, VAXX, Achieves Remarkable Top-line Growth in Financial Time-frame Ending September 2023



Vaxxinity Inc, a pioneering U.S. pharmaceutical company, has recently reported its financial results for the third quarter ended September 30, 2023. While the figures may seem lackluster at first glance, a detailed analysis reveals some promising signs of progress and potential for the future.
Break-even Achievement and Revenue Stability:
In the financial time-frame ending September 30, 2023, Vaxxinity Inc reached a significant milestone, reporting a break-even of $0.00 per share. This marks a vast improvement compared to the prior year's break-even result and the previous reporting season's loss of $-0.11 per share.










Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com